Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
about
Low-dose rate brachytherapy for men with localized prostate cancerEndocrine treatment in prostate cancerA prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder.Prostatourethral-rectal fistula after prostate brachytherapy.Prostate cancer immunotherapy at the dawn of the new millennium.Critical review of prostate cancer predictive toolsTreatment options after failure of local curative treatments in prostate cancer: a controversial issue.Brachytherapy versus radical prostatectomy.Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer.The evolving role of prostate brachytherapy.Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications.Prostate brachytherapy has come of age: a review of the technique and results.The treatment of prostate cancer: an overview of current options.Permanent seed implantation for localized adenocarcinoma of the prostate.Automatic brachytherapy seed placement under MRI guidance.Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer.Difference in the rate of rectal complications following prostate brachytherapy based on the prostate-rectum distance and the prostate longitudinal length among early prostate cancer patients.High-intensity focused ultrasound for prostate cancer: long-term followup and complications rate.Advances in radiotherapy for prostate cancer.Nomograms for prostate cancer.Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?The current role of imaging for prostate brachytherapyRepeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study.Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients.Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.Combining radiation therapy with interstitial radiation-inducible TNF-α expression for locoregional cancer treatment.Radical radiotherapy for high-risk prostate cancer in older menLong term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis.Comparison of seed loading approaches in prostate brachytherapy.Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy.Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy.Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.Monte Carlo validation and optimisation of detector packaging for spectroscopic dosimetry for in vivo urethral dosimetry during low dose rate brachytherapy.Evaluation of an automatic needle-loading system.Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.Impact of interseed attenuation and tissue composition for permanent prostate implants.Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy.COMP report: CPQR technical quality control guidelines for low-dose-rate permanent seed brachytherapy.
P2860
Q24235544-20577CB4-8EB4-4818-9201-6B9B40CD1FF3Q28378298-BEB79CDB-D0F4-44F2-A6B3-0A91C429FBE6Q30305730-1682F9D4-2173-4D51-BE91-32422F75988AQ30306333-7D0D69E2-5962-47FB-B134-F1D500C2F645Q30327421-631645D9-2ECE-49B7-B438-DB20D8A51703Q34104562-E159A5C0-BC1F-42CE-A8FD-C0B029A5044CQ34105531-F37E3C2F-4D2E-4090-8FE1-2EA671AA31FAQ34135234-7C0886D9-47F6-4DDC-8559-7E69D879EB3DQ34226325-2011F955-08DF-43E8-BADD-A1A7E4B41B2DQ34234541-850E5CCF-D609-4264-AB19-A5A50FEB1AEAQ34464321-F503A754-9AF2-4FC0-831E-07865BCF1CC0Q34539278-F5B04479-3DBD-443C-9A7E-EA88FCC8C26AQ34552438-33C83629-FBF2-493F-A02C-5415E26BBC94Q34707098-67A3ABAF-5EAA-4597-9BC6-4A7EFFE1D896Q34997252-C342A9DC-C878-4BC5-928C-6AC967313A51Q35797101-E6AEBF88-873B-42C8-8441-07BF9F3418D7Q36048698-CE58C59E-0AAF-4570-837C-C3D4CCFA203EQ36184597-94923153-5E64-4EB5-BC46-AF66199438E5Q36321668-CB9E6B13-970D-4C28-9B77-E403F2125154Q36532217-F854FCB8-9F1A-473F-B192-AAA1702CED2FQ36575837-1091C51D-E3E9-4939-A3F4-84D2A2AD4429Q36752462-9FB1C515-7F0C-42FE-B422-5EF1BAE72CE4Q37254687-95CA43EB-D8D5-495B-9A5C-41682F1E845AQ37490174-ED926E56-2F79-4C2B-90F2-14A414A89B5AQ38466338-7D443834-96D1-4910-AEC9-2C7FB5EBEB06Q39118986-0E4A01B0-2C12-42AF-8298-B9209EF468D0Q39619933-61470490-FB41-4F88-A47C-E4CC66F5CAF7Q39635530-FF9CF398-4E84-4561-B9EE-B87E263F8FF4Q41334584-34E2A127-DE4D-45F0-8102-5743E2BD3E2EQ41478724-8DD7572B-5141-4910-8750-4F9FE7CA6D6DQ42485004-53534664-C40B-4784-ADB8-551E8839B2C7Q43780960-76A6E349-A63A-4AF3-8696-099F9585B985Q44881565-282E2297-6837-4EEA-9360-DC132527B84EQ45351575-DB783DB3-98B1-464C-9A34-854F9A044641Q48035304-EE8FA59B-2175-4FF2-B41F-7E51CD49C0E3Q48633886-D0FAE1AF-8850-4A67-9754-246450FFE26CQ50753918-DB6EFA9D-E2F6-4507-AA72-646A00822379Q51153514-957FBCEB-E0F5-483A-A06C-57E35DD0EA1DQ51642053-18004141-42DE-4FEC-98C6-AFFEBEA9CDBDQ54941097-0A16F19D-E00F-4125-999E-6CC934CC2EF5
P2860
Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Ten-year disease free survival ...... ason grade prostate carcinoma.
@en
Ten-year disease free survival ...... ason grade prostate carcinoma.
@nl
type
label
Ten-year disease free survival ...... ason grade prostate carcinoma.
@en
Ten-year disease free survival ...... ason grade prostate carcinoma.
@nl
prefLabel
Ten-year disease free survival ...... ason grade prostate carcinoma.
@en
Ten-year disease free survival ...... ason grade prostate carcinoma.
@nl
P2093
P2860
P1433
P1476
Ten-year disease free survival ...... ason grade prostate carcinoma.
@en
P2093
Bartolucci AA
Elgamal AA
P2860
P304
P356
10.1002/(SICI)1097-0142(19980901)83:5<989::AID-CNCR26>3.0.CO;2-Q
P407
P577
1998-09-01T00:00:00Z